COFCO Biotechnology Co., Ltd.
000930.SZ · SHZ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | CN¥20,053 | CN¥20,379 | CN¥19,918 | CN¥23,560 |
| % Growth | -1.6% | 2.3% | -15.5% | – |
| Cost of Goods Sold | CN¥18,908 | CN¥19,798 | CN¥17,837 | CN¥21,122 |
| Gross Profit | CN¥1,146 | CN¥581 | CN¥2,081 | CN¥2,437 |
| % Margin | 5.7% | 2.9% | 10.4% | 10.3% |
| R&D Expenses | CN¥129 | CN¥165 | CN¥133 | CN¥119 |
| G&A Expenses | CN¥629 | CN¥574 | CN¥604 | CN¥577 |
| SG&A Expenses | CN¥823 | CN¥781 | CN¥804 | CN¥800 |
| Sales & Mktg Exp. | CN¥194 | CN¥207 | CN¥200 | CN¥223 |
| Other Operating Expenses | CN¥122 | CN¥208 | -CN¥207 | CN¥143 |
| Operating Expenses | CN¥1,074 | CN¥1,154 | CN¥730 | CN¥1,062 |
| Operating Income | CN¥72 | -CN¥572 | CN¥1,350 | CN¥1,375 |
| % Margin | 0.4% | -2.8% | 6.8% | 5.8% |
| Other Income/Exp. Net | CN¥58 | CN¥30 | CN¥10 | CN¥3 |
| Pre-Tax Income | CN¥129 | -CN¥543 | CN¥1,360 | CN¥1,377 |
| Tax Expense | CN¥84 | CN¥74 | CN¥299 | CN¥248 |
| Net Income | CN¥25 | -CN¥602 | CN¥1,059 | CN¥1,130 |
| % Margin | 0.1% | -3% | 5.3% | 4.8% |
| EPS | 0.014 | -0.327 | 0.57 | 0.605 |
| % Growth | 104.1% | -157.3% | -5.8% | – |
| EPS Diluted | 0.014 | -0.327 | 0.57 | 0.605 |
| Weighted Avg Shares Out | 1,861 | 1,842 | 1,865 | 1,866 |
| Weighted Avg Shares Out Dil | 1,861 | 1,842 | 1,865 | 1,866 |
| Supplemental Information | – | – | – | – |
| Interest Income | CN¥21 | CN¥11 | CN¥20 | CN¥15 |
| Interest Expense | CN¥108 | CN¥113 | CN¥91 | CN¥161 |
| Depreciation & Amortization | CN¥482 | CN¥467 | CN¥440 | CN¥435 |
| EBITDA | CN¥604 | CN¥47 | CN¥1,967 | CN¥2,119 |
| % Margin | 3% | 0.2% | 9.9% | 9% |